Deepbridge Capital has deployed over £50 million of capital into UK life sciences companies.
The Deepbridge Life Sciences EIS was launched in 2017 as our first life sciences focused EIS fund, providing private investors with access to a portfolio of early-stage investee companies across the biopharmaceutical, biotechnology, medical technology and digital healthcare sectors.
This capital has been provided UK-wide to 87 companies across the Deepbridge Life Sciences EIS and Deepbridge Life Sciences SEIS funds, with investee companies based across England, Northern Ireland, Scotland and Wales.
Dr Savvas Neophytou, Partner & Head of Life Sciences at Deepbridge Capital, says: “The global pandemic has seen an increase in investor and financial adviser interest in the life sciences sector. With so much media attention on vaccines, treatments and medical devices, this increase in appetite is perhaps not surprising. We are delighted to now have a portfolio of maturing companies that are progressing well, which is affirmed by the levels of co-funding and strategic partners we are helping our companies attract. Our companies are now working in over 30 countries and have operational bases across the globe."
Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).